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■ Abstract  Incidences of human 
transmissible spongiform encepha-
lopathies are monitored by na-
tional registries in the majority of 
countries in Western Europe. Dur-
ing the past 13 years incidences for 
Creutzfeldt-Jakob disease (CJD) in 
Switzerland fluctuated between 0.4 
and 2.63 cases/106 inhabitants. We 
have compared clinicpathological 
patient profiles including geo-
graphic and gender distribution, 
age at disease onset, duration of 
disease, clinical symptoms, and 
recognized or hypothetical risk 
 factors for CJD, genetic risk factors, 
biochemical and histopathological 
data for two cohorts of Swiss 
 sporadic CJD patients from years 
of regular sporadic CJD incidence 
(1996–2000, mean incidence 1.3 
cases/106 inhabitants, n = 47) to 
Swiss sporadic CJD patients from 
years of elevated sporadic CJD inci-
dence (2001–2004, mean incidence 
2.3 cases/106 inhabitants, n = 73). 
Sporadic CJD patients from the 
 cohort with elevated sporadic CJD 
incidence presented with a higher 
frequency of rare sporadic CJD 
subtypes. Patients of these sub-
types were significantly older and 
showed a skewed male/female ratio 
when compared to published 
 patients of identical sporadic 
CJD-types or to patients from the 
1996–2000 cohort and indicates 
that improved detection of rare 
sporadic CJD subtypes may have 
contributed to increased incidence. 
■ Key words  Creutzfeldt-Jakob 
disease · prions · dementia · 
 epidemiology
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Introduction
Prion diseases or transmissible spongiform encepha-
lopathies are fatal neurodegenerative diseases affecting 
both humans and animals [23]. Neuropathologically, 
they are characterized by spongiosis, gliosis, neuronal 
loss and the accumulation of an aberrantly folded iso-
form of the normal cellular prion protein, termed PrPSc, 
which is an essential component of the infectious agent 
[22]. The most common human prion disease, sporadic 
Creutzfeldt-Jakob disease (sCJD) comprises about 85 % 
of all human prion diseases and is of unknown origin. 
sCJD may present with a marked clinical heterogeneity. 
By combining clinical features with histopathological 
analysis, the status of a polymorphism on the gene en-
coding the prion protein as well as biochemical analysis 
of PrPSc, several sCJD types may be differentiated [14, 
19].
About 15 % of human prion diseases are caused by 
known mutations in the prion protein gene (PRNP) and 
may be inherited as autosomal dominant traits [15]. A 
further subset of human prion diseases are acquired by 
exposure to infectious prions, in the framework of neu-
rosurgical interventions or through hormone substitu-
tion, and are referred to as iatrogenic CJD [2]. A novel 
human prion disease, variant CJD (vCJD), is thought to 
be caused by exposure to BSE prions via uptake of BSE-
contaminated material or by transfusion of vCJD con-
taminated blood products [3, 13, 20, 29]. 
The appearance of vCJD and its development into an 
epidemic in the UK has led to the establishment of CJD 
surveillance centres among European countries which 
carry out active surveillance according to standardized 
protocols in order to identify and monitor the epidemi-
ology of human prion diseases (http://www.eurocjd.
ed.ac.uk/).
In 1995, the Swiss National Reference Centre of Prion 
Diseases (NRPE) was established and active CJD sur-
veillance has bee conducted since 1996. This includes 
clinical and epidemiological assessment of patients, ge-
netic analysis, as well as pathological and biochemical 
analysis of tissue specimens [25].
From 1996 to 2000, sCJD affected between seven to 11 
patients per year, corresponding to an annual incidence 
of 1.0 to 1.4 patients per million per year which is well in 
line with the presumed global incidence of sCJD, about 
one patient per million per year [11]. However, in 2001 
the number of sCJD patients increased to 18, translating 
to an incidence of 2.5 patients per million per year [10]. 
In the subsequent three years, the incidence remained 
elevated, ranging from 1.4 to 2.0 per million per year 
(Fig. 1).
The aim of the present study was to compare clinical, 
genetic, biochemical and pathological features of sCJD 
in two cohorts of patients. The first cohort comprises 
patients from the years 1996 to 2000 with an average in-
cidence of sCJD of 1.3 per million per year, whereas the 
second cohort comprises patients from the years 2001 to 
2004 with an average incidence of sCJD of 2.3 per mil-
lion per year. 
Patients and methods
■ Patients
In this study, 120 sporadic CJD patients, who were reported to the 
Swiss National Reference Centre of Prion Diseases (NRPE) and to the 
Swiss Federal Office of Health between 1996 and 2004, were included. 
Clinical information including assessment was carried out according 
to standardized protocols. We collected tissues at necropsy from pa-
tients according to established safety and ethical guidelines [4]. The 
group comprises 109 ‘definite’, neuropathologically-proven, and 11 
‘probable’ CJD patients, corresponding to a proportion of ‘definite 
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Fig. 1  Incidence of sCJD from 1996–2007 in Swit-
zerland. From 1996 to 2000, the number of sporadic 
CJD patients (grey bars) ranged from 8 to 11 per year, 
corresponding to an annual incidence of sCJD deaths 
(black diamonds) of 1.3–1.4 cases per million. From 
2001 to 2004, the incidence has increased to 2.2–2.5 
cases per million per year
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CJD’ of 91 %. Clinical diagnosis of ‘probable CJD’ was carried out ac-
cording to established criteria [8].
■ Technical investigation
Cerebrospinal fluid (CSF) samples from suspected CJD patients were 
sent from notifying hospitals. The 14-3-3 test was performed accord-
ing to an established protocol [31]. Original electroencephalogram 
(EEG) recordings were provided from notifying hospitals and evalu-
ated for the presence of periodic sharp wave complexes (PSWC) using 
standardized criteria [26]. Magnet resonance imaging (MRI) scans 
were analysed for detection of hyperintense basal ganglia on T2-/
FLAIR and diffusion-weighted images (DWI).
■ Genetic analysis
Genetic analysis of PRNP was performed on genomic DNA isolated 
from blood or brain tissue according to standard procedures [30]. In 
order to exclude disease-associated mutations and to determine the 
methionine/valine polymorphism on codon 129 the entire open read-
ing frame of the protein was sequenced.
■ Neuropathological examination
Specimen from the following brain regions were examined: frontal, 
parietal, occipital, and temporal cortex, putamen, thalamus, midbrain, 
medulla oblongata and cerebellum. Neuropathological examination 
included assessment of spongiosis, neuronal loss, gliosis and detec-
tion of PrP by immunohistochemistry. 
■ Immunohistochemistry
Conventional immunohistochemical staining was performed on for-
malin-fixed, paraffin embedded tissue. Sections were cut (3 μm), fol-
lowing deparaffinization and pre-treatment including hydrolytical 
autoclaving for 30 min at 121 °C, formic acid for 2.5 min and guani-
dinium thiocyanate for 30 min at 4 °C. For detection of PrPSc, sections 
were then probed with monoclonal anti-PrP antibody 3F4 according 
to published methods [25]. 
■ Western blot analysis
Western blot analysis for detection of PrPSc in brain samples of sCJD 
patients was performed according to published protocols [21]. PrPSc 
was typed according to the size of protease-resistant unglycosylated 
PrPSc fragment and designated as either PrPSc type 1 (unglycosylated 
fragment running at 21 kDa) or PrPSc type 2 (unglycosylated frag-
ment running at 19 kDa) [5, 7, 19].
■ Triplot of glycoform profiles
Glycoform ratios were compared in a triangular plot correlating the 
intensities of diglycosylated, monoglycosylated and unglycosylated 
bands of PrPSc according to published protocols [25]. Densitometric 
analysis of PrP glycoforms was performed using a one-dimensional 
software analysis program (Quantity One, Biorad).
■ Statistical analysis
The two cohorts were compared by Student’s t-test for independent 
samples with unequal variances and chi square test. P-values of < 0.05 
were considered significant. As statistical software for calculations, 
Epi Info(tm) (Version 3.4) and SPSS® (Version 13) were used.
Results
■ Incidence of sCJD in Switzerland from 1996 to 2007 
Supplementary Table 1 shows the yearly incidence of 
sporadic, genetic and iatrogenic CJD from the years 1996 
to December 2007. The mean incidence of sCJD in the 
period 1996 to 2000 was 1.290 cases/106 inhabitants 
(95 % C.I. 1.062–1.517) which was significantly higher 
(p-value 0.000; Wilcoxon rank-sum test) than the mean 
incidence in the period 2001 to 2004 of 2.318 cases/106 
inhabitants (95 % C.I. 2.037–2.599). By including the 
most recent sCJD incidence data into this analysis, the 
differences between mean incidences of sCJD from 
1996–2000 to 2001–2007 were still statistical significante 
(from 2001 to 2007, the mean incidence of sCJD was 
2.009 cases/106 inhabitants (95 % C.I. 1.592–2.426), p-
value of 0.0185 (Wilcoxon rank-sum test)).
■ Patient characteristics of the cohorts 1996–2000 
and 2001–2004 
From 1996–2000, 47 sCJD patients were identified, 46 
patients were classified as definite and one as probable 
sCJD. 26 of them were male and 21 were female resulting 
in a male to female ratio of 1.1:1. From 2001–2004, 73 
sCJD patients were diagnosed, 63 definite and 10 prob-
able sCJD (Fig. 1). 45 of them were male and 28 were fe-
male resulting in a male to female ratio of 1.6:1 (Fig. 2 A, 
B). The overrepresentation of male sCJD patients for the 
years 2001–2004 is statistically significant (p < 0.036, chi 
square test) when compared to the age-matched normal 
population of Switzerland (Odds ratio 2.05; 95 % CI 
1.22–3.46; p = 0.037, chi square test). 
■ Mean age at onset and disease duration 
Table 1 presents collective data on age at onset and dis-
ease duration of both patient cohorts substratified by 
sCJD subtypes. From 1996–2000, in depth data on mo-
lecular CJD subtypes was available in 25 of 47 patients 
and from 2001–2004 in 60 of 73 patients. 
From 1996–2000, the mean age at onset of disease in 
sCJD patients was 66 years (n = 47, standard deviation 
(SD) ± 9 years). Age at onset varied between CJD sub-
types: MM1 patients presented the youngest group with 
a mean age at onset of 65 years (n = 18, SD ± 8 years). 
Patients of the other groups were older: VV2 and MV2 
subtypes showed a mean age at disease onset of 68 (n = 1) 
and 69 (n = 3) years, whereas for patients of the MM2 
and MV1 subtype, age at onset was 72 (n = 1) and 77 
(n = 2) years.
Mean disease duration in this time period was 6 
months (SD ± 5 months). Disease duration varied among 
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CJD subtypes. The shortest disease course was observed 
in the MM1 (5 months, SD ± 6 months) and VV2 sub-
group. Patients with MV1 and MV2 phenotype had lon-
ger disease durations of 3 and 12 months for MV1 and 
10 months for MV2. 
In the 2001–2004 cohort, the mean age at disease on-
set for sCJD patients was 68 years (n = 73, SD ± 10 years). 
Patients of the MM1 subgroup had a mean age at disease 
onset of 70 years (n = 33, SD ± 9 years), whereas patients 
belonging to the MV2 and VV2 subgroup of sCJD pa-
tients had a mean age at disease onset of 69 years (n = 11, 
SD ± 11 years) and 66 years (n = 10, SD ± 10 years), re-
spectively. 
Mean disease duration in the years 2001–2004 was 6 
months (SD ± 6 months). MM1 and VV2 patients had 
short disease durations of 4 months (SD ± 2 months) 
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Table 1  Clinical characteristics of Swiss CJD patients from 1996–2000 and 2001–2004
 Time range Subtypes n°of cases (% of total) Mean age at disease onset (years)
(range; ± SD)
Mean disease duration (month)
(range; ± SD)
total m f total m f total m f
 1996–2000 MM1 18 (72)  6 12 65 (48–80; 8) 67 64  5 (2–27; 6)  3  5
MV1  2 (8)  1  1 77 (77; 0) 77 77  8 (3–12; 6) 12  3
MV2  3 (12)  3  0 69 (54–81; 14) 69  – 10 (2–21; 10) 10  –
VV2  1 (4)  1  0 68 68  –  4  4  –
MM2  1 (4)  0  1 72  – 72  5  –  5
 2001–2004 MM1 33 (55) 18 13 70 (41–82; 9) 69 70  4 (1–11; 2)  4  4
MV1  2 (3)  1  1 71 (60–83; 16) 83 60  3 (3–4; 1)  4  3
VV1  1 (1.7)  1  0 63 63  –  4  4  –
MV2 11 (18.3)  8  3 69 (48–84; 11) 66 76 11 (2–28; 7) 11 11
VV2 10 (16.7)  7  3 66 (47–81; 10) 68 62  7 (4–14; 3)  7  9
MM2  3 (5)  2  1 64 71 49  7 ( 49–72; 13)  9  4
Fig. 2  Clinical characterization of 
sCJD patients from 1996–2000 and 
2001–2004 (n = 120). Shown are 
demographic characteristics of two 
sCJD cohorts (1996 to 2000 and 2001 to 
2004). A Ratios of identified probable to 
definite sCJD patients from 1996–2000 
(n = 47) compared to 2001–2004 
(n = 73). B Gender ratios of CJD patients 
from 1996–2000 and 2001–2004. Note: 
Increase in male to female ratio (1.6:1) 
2001–2004 when compared to the 
1996–2000 cohort or other published 
cohorts. C Distribution of the polymor-
phism at PRNP codon 129 (n = 91). sCJD 
patients are predominantly homozygous 
for methionine (70 %) or valine (18 %) 
[1]. Note: Higher frequency of MV and 
VV patients in the years 2001–2004 
when compared to the 1996–2000 
cohort or other published cohorts. D 
Analysis of the molecular CJD subtype 
based on PrPSc type and codon 129 
genotpye (n = 90): Higher frequency of 
the MV2 and VV2 subtype in 2001–2004 
when compared to 1996–2000 or other 
published cohorts [12, 19]
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and 7 months (SD ± 3 months), whereas MV2 patients 
presented with the longest disease duration of 11 months 
(SD ± 7 months).
Among all atypical cases combined (i.e. VV1, MM2, 
MV2 and VV2 subtypes), mean age at onset was 67.3 
years (n = 30). In the 1996–2000 cohort (n = 5) it was 69.4 
years, and in the 2001–2004 cohort (n = 25) it was 67.0 
years. 
■ Detailed patients characteristics of the sCJD cohort 
2001–2004
A detailed analysis, including clinical signs and results 
of technical investigations was carried out for the 2001–
2004 cohort. Collective data were available in 51 of 73 
patients on clinical signs (neurological and psychiatric) 
and in 53 of 73 patients on results of technical investiga-
tions. We did not find evidence for regional clustering or 
iatrogenic and zoonotic exposure in this group of pa-
tients when assessing recognized or hypothetical risk 
factors for CJD (data not shown).
■ Neurological and psychiatric signs
Dementia was the most common clinical sign in all sub-
groups (not listed) followed by focal neurological fea-
tures such as cerebellar signs, myoclonus, pyramidal 
and eyxtapyramidal signs, presence of primitive reflexes 
and akinetic mutism (Table 2). MM1 patients presented 
mainly with rapid progressive dementia, cerebellar 
signs, myoclonus and akinetic mutism. MV2 patients 
showed dominantly extrapyramidal and early cerebellar 
signs, whereas VV2 patients were mainly characterized 
by late-onset dementia and early cerebellar signs.
Psychiatric symptoms were frequent in all subtypes. 
Patients of all subgroups were similarly affected by vis-
ual hallucination and anxiety. Depression, low mood 
and apathy were more frequent in MM1 patients than in 
MV2 or VV2 patients, whereas these patients showed a 
higher frequency of delusion and aggressive behaviour 
than MM1 patients.
■ Results from technical investigations
A variety of technical investigations support the clinical 
diagnosis of sCJD. However, the sensitivity of CJD-typi-
cal findings in different investigations, such as MRI (hy-
perintense basal ganglia), cerebrospinal fluid analysis 
(elevation of the 14-3-3 protein) or EEG (PSWC) is lim-
ited. In our cohort, CSF analysis was the most sensitive 
test in all investigated groups with an overall sensitivity 
of 91.5 % (Table 3). The overall sensitivity of EEG was 
limited. The highest sensitivity for this examination was 
66.7 % for the MM1 group of patients. Sensitivities for 
patients of the MV2 and VV2 subtype of sCJD were 18 % 
and 10 %, respectively. Typical MRI changes were mainly 
observed in MV2 (75 %) and in MM1 (60 %) patients, 
respectiely, whereas in VV2 patients, CJD-typical MRI 
changes were less frequently (40 %).
By analysing CJD-typical MRI signs in CJD patients 
from 2001–2004 including novel imaging methods, such 
as diffusion-weighted imaging (DWI), we observed an 
increase of the ratio of CJD-typical MRI in the years 
2001–2004 (Fig. 3).
■ Genetic analysis of sCJD patients
Genetic analysis, which included sequencing of PRNP 
and determination of a polymorphism on codon 129, 
was carried out in 91 patients (1996–2000 cohort, 28 of 
47 sCJD patients; 2001–2004 cohort, 63 of 73 patients). 
In the group of patients from 1996–2000, 20 patients 
(71.4 %) were homozygous for methionine (MM), 5 pa-
tients (17.9 %) were heterozygous for methionine and 
valine (MV) and 3 patients (10.7 %) were homozygous 
for valine (VV). 
In the group of patients from 2001–2004, 39 patients 
(62 %) were MM, 14 patients (22.2 %) were MV and 10 
patients (15.9 %) were VV (Fig. 2 C). 
Table 2  Neurological and psychiatric signs in Swiss sCJD patients 2001–2004
 sCJD subgroup MM1
(n = 30)
MV2
(n = 11)
VV2
(n = 10)
 Frequency of neurological signs (%) 
  cerebellar signs 83.3 81.8 80
  myoclonus 76.7 54.5 80
  primitive reflexes 71.4 36.4 70 
  extrapyramidal signs 60 90.9 60
  akinetic mutism 63.3 54.5 50
  visual disturbances 43.3 36.4 30
  dizziness 40 63.6 60
  other involuntary movements 33.3 45.5 20
  oculomotoric signs 30  9.1 50
  pyramidal signs 23.3 18.2 40
  seizures 13.3  0 10
  headache 16.7  9.1 30
  pain 10  9.1 10
  other sensory disturbances 16.7  9.1 10
  pseudobulbar signs  7.1 45.5 30
  neurogenic muscle wasting  3.6  0 10
 Frequency of psychiatric signs (%)
  visual hallucination 41.9 54.5 40
  anxiety 29.0 36.4 30
  depression 25.8  9.1 10
  low mood and apathy 25.8  9.1 20
  delusion 19.4 36.4 20
  aggression 16.1 27.3 40
  social withdrawal 12.9 18.2 10
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■ Molecular sCJD subtypes 
The molecular sCJD subtype, based on the combination 
of codon 129 genotype and PrPSc type in Western blot 
and neuropathological analysis, could be assessed in 85 
sCJD patients (25 of 47 for the 1996–2000 cohort, 60 of 
73 for the 2001–2004 cohort, Table 1). 
The most prominent sCJD subtype in the patient 
group from 1996–2000 was MM1 (72 %, n = 18), followed 
by MV2 (12 %, n = 3), MV1 (8 %, n = 2) and solitary cases 
of MM2 (4 %) and VV2 (4 %). From 2001–2004, the ratio 
in the subtype distribution changed. MM1 was again the 
most frequent subtype with 55 % (n = 33) of the patients, 
followed by MV2 (8.3 %, n = 11), VV2 (16,7 %, n = 10), 
MM2 (5 %, n = 3) as well as cases of MV1 (3 %, n = 2) and 
VV1 (1,7 %, n = 1). Interestingly, there was a significant 
increase of atypical cases (VV1, MM2, MV2 and VV2) in 
the 2001–2004 cohort (43 %) when compared to the 
1996–2000 cohort (20 %; n = 83 odds ratio 3.03; 95 % CI 
2.47–3.72; p < 0.001, chi square test). Results were similar 
when taking into account all patients (including the 
non-specified sCJD subtypes): the ratio increased from 
11 % atypical vs. 43 % typical cases in the 1996–2000 co-
hort to 34 % atypical vs. 45 % typical cases in the 2001–
2004 cohort (n = 120; odds ratio 3.04; 95 % CI 2.34–3.96; 
p < 0.001, chi square test).
Neuropathological analysis of above mentioned pa-
tients confirmed published data [14]. Patients belonging 
to the MM1 group showed synaptic and perivacuolar 
PrP deposition, whereas in MV1 and MV2 patients syn-
aptic and plaque like deposits could be identified. In pa-
tients belonging to the VV2 group, PrP was deposited in 
band-like arrangements, perineurally and plaque-like 
(Fig. 4). 
■ Triplot analysis of glycoform ratios
Glycoform ratios of sCJD patients from 1996–2000 and 
from 2001–2004 were compared in a triangular plot cor-
relating the intensities of the diglycosylated, monogly-
cosylated and unglycosylated bands of PrPSc (Fig. 5). 
Patients with sCJD from 1996–2000 and 2001–2004 clus-
ter in the same area of the plot. Non-Swiss control pa-
tients of various sCJD subtypes show similar glycoform 
ratios, whereas patients with vCJD segregate in a distinct 
region of the plot.
Discussion
From 2001–2004, Switzerland has been reporting an in-
creased incidence of sCJD patients, when compared to 
earlier years of active CJD surveillance, raising ques-
tions about the origin of this phenomenon [9, 10]. In this 
study, we analysed two sCJD cohorts. The first cohort 
comprised sCJD patients from a period with “regular” 
sCJD incidence (1996 to 2000). The second cohort com-
Table 3  Sensitivity of diagnostic tests in CJD subtypes from 2001–2004 (in %)
 CJD subtype n typical EEGa abnormal EEGb normal EEG 14-3-3 positive 14-3-3 trace 14-3-3 negative typical MRIc abnormal MRId normal MRI
 MM1 27 66.7  33.3   0  85.2 3.7 11.1  62.1  20.7 17.2
 MV1  2  0 100   0 100 0  0   0 100  0
 VV1  1  0   0 100 100 0  0 100   0  0
 MM2  2  0 100   0 100 0  0  50  50  0
 MV2 11 18.2  63.6  18.2 100 0  0  75.0  25.0  0
 VV2 10 10.0  50.0  10 100 0  0  44.4  33.3 22.2
 Total 53 40.4  51.9   7.7  91.5 2,1  6.4  60.0  26.0 14.0
a generalized PSWC; b mild to moderate EEG changes, diffuse slowing; c hyperintense signal in basal ganglia and /or cortical; d cerebral atrophy
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Fig. 3  Ratios of MRI results in the years 2001–2004. Shown is the temporal 
development of imaging results in sCJD patients. Note: increase in CJD-typical MRI 
over time may be attributed the introduction of (DWI)-MRI
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prised sCJD patients from a period with elevated sCJD 
incidence (2001–2004). We compared differences in clin-
icopathological profiles including CJD subtypes between 
both cohorts and to published data [14, 19]. In an initial 
analysis, we formulated several hypotheses concerning 
the increase in sCJD in Switzerland [9]. One hypothesis 
comprised that it might be due to statistical fluctuation. 
We consider this an unlikely explanation for the ob-
served increase in incidence since the rise in incidence 
between the 1996–2000 and 2001–2004 cohorts was sta-
tistically significant. Yet, this possibility cannot be dis-
missed unequivocally given that the statistical signifi-
cance is marginal if most recent incidence data 
(2001–2007) are included in the analysis.
Another idea implied that the heightened incidence 
might be related to ascertainment bias due to a tempo-
rarily heightened awareness of the disease. In the most 
recent years, the observed incidence in sCJD deaths 
(2005: 10 cases; 2006: 11 cases, 2007: 15 cases) dropped 
to levels just slightly above the 1996–2000 period (http://
www.eurocjd.ed.ac.uk/allcjd.htm). The recent develop-
ment may reflect decreased awareness of prion diseases 
in the general public due to decreased media coverage in 
recent years. The hypothesis of ascertainment bias is 
further supported by data from European countries re-
porting increased CJD incidences related to heightened 
awareness due to the introduction of novel diagnostic 
tools, such as measurement of protein 14-3-3 in the CSF 
[18, 24]. Typically, increased incidence of CJD attributed 
to heightened awareness goes along with an increase in 
the median age of CJD patients [28]. This is believed to 
be caused by more frequent recognition of CJD in eld-
erly demented patients. Although the mean age at onset 
for the Swiss sCJD cohort 2001–2004 is similar when 
compared to that of 1996–2000, it is obvious that Swiss 
sCJD patients of the rare, and clinically-atypical, sCJD 
subtypes were on average 5 years (VV2) to 10 years 
(MV2) older than those from large published sCJD co-
Fig. 4  Histopathological findings in frontal cortex of sCJD patients. HE stain (A–D) and PrP immunostain (E–H) shows spongiform changes and CJD-type specific PrP 
deposits. sCJD patients of the MM1 group show synaptic PrP deposition (E), whereas MV1 patients and MV2 patients show additional plaque like or perineural PrP deposits 
(F, G). In patients belonging to the VV2 group, PrP deposits in band-like arrangements and perineurally (H)
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horts [19, 32]. Although these data do not clearly speak 
in favour of an ascertainment bias, the fact that the 
2001–2004 cohort of sCJD patients showed a higher fre-
quency of the less common MV2 subtype when com-
pared to the 1996–2000 cohort and to previous publica-
tions, in concert with the fact that there is a significant 
increase in the median age of this patient group is re-
markable [12, 19, 32]. This observation might be of par-
ticular clinical interest as it highlights the possibility of 
less common variants such as the MV2 subtype, in older 
patients with atypical clinical presentations. 
A genetic origin for the rise in CJD incidence seems 
unlikely as there is no increased incidence of genetic 
CJD from 2001 onwards. Finally, an acquired origin of 
the rise in incidence, in the framework of iatrogenic or 
zoonotic transmission which had initially been consid-
ered, remains an unlikely option, since neither a iatro-
genic nor a zoonotic exposure is evident and we did not 
observe regional clustering. 
Other differences between the two cohorts which do 
not support or dismantle any of the hypotheses men-
tioned above, relate to gender distribution. In 2001–2004 
the male to female ratio was (1.6:1), whereas the male to 
female ratio in the years 1996–2000 was (1.1:1) which is 
similar to that of published studies [32]. Interestingly, 
when analysing the gender distribution in different CJD 
subtypes from 2001–2004, we observed an over-repre-
sentation of the MV2 and VV2 subtype in male (70 %) 
versus female patients (30 %), whereas this phenomenon 
could not be observed in MM1 patients.
Results in routine investigations in patients from 
2001–2004 were similar to those previously described [6, 
17]. CSF analysis was the most sensitive test in all inves-
tigated groups with an overall sensitivity of 91.5 %. In-
terestingly, all MV2 and VV2 patients showed a positive 
14-3-3 test. This is surprising, as lower 14-3-3 test sensi-
tivities have been described in these subtypes in recent 
publications [6, 16]. Typical MRI changes were mainly 
observed in MV2 (75 %) and in MM1 patients (60 %), 
while in VV2 patients, CJD-typical MRI changes were 
less frequent (40 %). These results are again comparable 
to published data and support the importance of MRI as 
a diagnostic tool for the detection of less common CJD 
subtypes such as MV2 [16, 27]. Additionally, we show a 
tendency towards improved diagnostic specificity in 
sensitive imaging methods, such as DWI-MRI, for the 
years 2001–2004. This is in agreement with recent stud-
ies stressing the importance of sensitive imaging meth-
ods in the early diagnosis of sCJD [27]. In summary, this 
analysis confirms our initial finding of an increased in-
cidence of sCJD in Switzerland. Although, the reason for 
this phenomenon remains unexplained to date, our 
analysis demonstrates that patients from the years 
2001–2004 with increased sCJD incidence differ in sev-
eral aspects from published sCJD cohorts. The fact that 
the MV2 subgroup of patients showed an increase in 
mean age at disease onset when compared to published 
cohorts, together with the fact that these patients dem-
onstrate distinct features in sensitive imaging methods, 
may indicate that improved detection of these patients 
has contributed to the rise in sCJD incidence. Further 
studies investigating biochemical and genetic aspects 
will contribute to our understanding of the mechanisms 
underlying sCJD. 
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